<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1453</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2021-17-3-154-164</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>PROBLEMS IN ORGANIZATION OF HEALTH CARE SERVICE IN ONCOUROLOGICAL DISEASES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ВОПРОСЫ ОРГАНИЗАЦИИ ЗДРАВООХРАНЕНИЯ ПРИ ОНКОУРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЯХ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Organizing the national prostate cancer audit in the UK (review of foreign literature)</article-title><trans-title-group xml:lang="ru"><trans-title>Организация национального аудита качества онкологической помощи при раке предстательной железы в Великобритании (обзор иностранной литературы)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0745-9474</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreev</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Андреев</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dmitriy Anatol'evich Andreev</p><p>9 Sharikopodshipnikovskaya St., Moscow 115088</p></bio><bio xml:lang="ru"><p>Дмитрий Анатольевич Андреев</p><p>115088 Москва, Шарикоподшипниковская ул. 9</p></bio><email>AndreevDA@zdrav.mos.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1825-1871</contrib-id><name-alternatives><name xml:lang="en"><surname>Zavyalov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Завьялов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>9 Sharikopodshipnikovskaya St., Moscow 115088</p></bio><bio xml:lang="ru"><p>Александр Александрович Завьялов</p><p>115088 Москва, Шарикоподшипниковская ул. 9</p></bio><email>ZavyalovAA3@zdrav.mos.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute for Healthcare Organization and Medical Management, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУ г. Москвы Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения г. Москвы</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-11-11" publication-format="electronic"><day>11</day><month>11</month><year>2021</year></pub-date><volume>17</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>154</fpage><lpage>164</lpage><history><date date-type="received" iso-8601-date="2021-06-21"><day>21</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-10"><day>10</day><month>10</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1453">https://oncourology.abvpress.ru/oncur/article/view/1453</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> The growing number of patients with prostate cancer (PCa) imposes additional requirements on the quality control system in healthcare, including ensuring the widespread availability of innovative algorithms for early diagnosis and treatment. One illustrative example of quality management initiatives is national PCa audit in the UK. Objective. Highlighting the approaches to quality assessments within audit of PCa care in the UK.</p><p><bold>Materials and methods</bold>. The relevant scientific data have been retrieved from Google and PubMed. The search horizon covered the last 10 years. The queries included such wording as: "prostate cancer" AND "audit" OR/AND "Great Britain" AND "quality assurance", etc.</p><p><bold>Results.</bold> At least four basic parameters were used as signal indicators to check the consistency and overall quality of the collected data on PCa patients in England and Wales. The fundamental arrangement of clinical quality indicators for PCa care comprised not less than fourteen measures. The outliers for some indicators were allocated into two groups using such criteria as: 1) more than three standard deviations from the national average (definition of an alarm); 2) more than two but below three standard deviations from the national average (definition of an alert). The outlier policy is usually applied for three treatment outcome performance indicators.</p><p><bold>Conclusion.</bold> The multidisciplinary teams must actively collaborate to provide the best standards of cancer care to the community. The introduction of multicriterial assessments to monitor the performance of highly specialized professional groups would bring a great benefit for cancer patients, particularly, through increasing the affordability of state-of-the-art medical algorithms across the counties.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Рост числа больных раком предстательной железы (РПЖ) предъявляет дополнительные требования к системе контроля качества в здравоохранении, включающие обеспечение повсеместной доступности новых алгоритмов ранней диагностики и лечения. Одной из показательных инициатив по управлению качеством являются организация и проведение национального аудита оказания медицинской помощи при РПЖ в Великобритании. Цель обзора - обобщение информации по методологии проведения оценок качества в проспективном аудите медицинской помощи при РПЖ в Великобритании.</p><p><bold>Материалы и методы.</bold> Поиск источников научной информации проводили в Google и PubMed. Горизонт поиска включал последние 10 лет. В поисковых запросах применяли термины: "prostate cancer" AND "audit" OR/AND "Great Britain" AND "quality assurance" и т. д.</p><p><bold>Результаты.</bold> Сигнальными маркерами качества собираемых сведений о больных РПЖ в Англии и Уэльсе являются 4 ключевых параметра. Группа базовых клинических критериев качества онкологической помощи при РПЖ представлена 14 переменными. Определены 2 класса индикаторов «нарушений»: 1) тревожные значения - результаты оценки эффективности отличаются более чем на 3 стандартных отклонения от среднего по стране; 2) предупреждающие значения - показатель эффективности в интервале более 2, но менее 3 стандартных отклонений от среднего национального значения в течение 2 лет подряд.</p><p><bold>Заключение.</bold> Лечение РПЖ должно проводиться с участием специалистов мультидисциплинарных бригад. Разработка и внедрение мультипараметрических оценок организации специализированной экспертной медицинской деятельности (способов оценки качества работы специализированных профессиональных групп) создают необходимые условия для повышения доступности прорывных методов диагностики и лечения злокачественных новообразований в регионах.</p></trans-abstract><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>malignant tumor</kwd><kwd>quality control and quality assurance</kwd><kwd>cancer care</kwd><kwd>audit</kwd><kwd>UK</kwd><kwd>review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>злокачественное новообразование</kwd><kwd>контроль качества</kwd><kwd>организация онкологической помощи</kwd><kwd>аудит</kwd><kwd>Великобритания</kwd><kwd>обзор</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>World Cancer Research Fund International. Prostate cancer statistics. American Institute for Cancer Research. [Internet]. 2021 (cited 2021 May 28). Available at: https://www.wcrf.org/dietandcancer/prostate-cancer-statistics/.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: AD. Kaprin, V.V. Starinskiy, A.O Shachzadova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. ПА. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>National Prostate Cancer Audit. Quality Improvement. [Internet]. 2021 (cited 2021 Jun 18). Available at: https://www.npca.org.uk/quality-improvement/.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Aggarwal A., Nossiter J., Cathcart P. et al. Organisation of prostate cancer services in the English National Health Service. Clin Oncol (R Coll Radiol). 2016;28(8):482—9. DOI: 10.1016/j.clon.2016.02.004.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Van Rijssen L.B., Koerkamp B.G., Zwart M.J. et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford) 2017;19(10):919—26. DOI: 10.1016/j.hpb.2017.06.010.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Aggarwal A., Cathcart P., Payne H. et al. The National Prostate Cancer Audit — introducing a new generation of cancer audit. Clin Oncol (R Coll Radiol) 2014;26(2):90—3. DOI: 10.1016/j.clon.2013.10.006.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Aggarwal A., Nossiter J., Parry M. et al. Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. Lancet Oncol 2021;22(5):e207—15. DOI: 10.1016/S1470-2045(20)30558-1.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>National Prostate Cancer Audit. Annual Report 2020 Executive Summary. [Internet]. 2021 (cited 2021 Jun 16). Available at: https://www.npca.org.uk/reports/npca-executive-summary-2020/.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Healthcare Quality Improvement Partnership (HQIP). National Prostate Cancer Audit. Annual Report 2020. Methodology Supplement. [Internet]. 2021 (cited 2021 Jun 11). Available at: https://www.npca.org.uk/reports/npca-methodology-supplement/.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>NPCA Annual Report 2020 Infographics. [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/reports/npca-annual-report-2020-infographics/.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>National Prostate Cancer Audit (NPCA). Annual Report 2020. Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019 (published January 2021). [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/reports/npca-annual-report-2020/.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Nossiter J., Sujenthiran A., Charman S.C. et al. Robot-assisted radical prostatectomy vi laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. Br J Cancer 2018;118(4):489—94. DOI: 10.1038/bjc.2017.454.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Szymanski K.M., Wei J.T., Dunn R.L., Sanda M.G. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76(5):1245—50. DOI: 10.1016/j.urology.2010.01.027.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>National Prostate Cancer Audit (NPCA). NPCA Outlier Policy 2020. [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/resources/npca-outlier-policy-2020/.</mixed-citation></ref></ref-list></back></article>
